Scarica l'app Stockscreener
19.36
0.62%
-0.0981
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché TVTX Giù?
Forum
Previsione
Frazionamento azionario
Travere Therapeutics Inc Borsa (TVTX) Ultime notizie
FY2024 Earnings Forecast for TVTX Issued By Leerink Partnrs - MarketBeat
Cantor Fitzgerald Predicts TVTX FY2025 Earnings - MarketBeat
What is Leerink Partnrs’ Estimate for TVTX FY2026 Earnings? - Defense World
Leerink Partnrs Issues Optimistic Estimate for TVTX Earnings - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by Assenagon Asset Management S.A. - Defense World
Research Analysts Issue Forecasts for TVTX FY2024 Earnings - Defense World
HC Wainwright Issues Pessimistic Forecast for TVTX Earnings - MarketBeat
What is HC Wainwright’s Estimate for TVTX FY2029 Earnings? - Defense World
FY2029 Earnings Forecast for TVTX Issued By HC Wainwright - MarketBeat
Nephrotic Syndrome Market Set to Grow Substantially Through 2034, DelveInsight Projects | GlaxoSmithKline, Goldfinch Bio, Inc., Travere Therapeutics, Inc., Aurinia Pharmaceuticals, Bristol-Myers Squib - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Price Target Raised to $22.00 at HC Wainwright - MarketBeat
Alport Syndrome Market to Show Remarkable Growth Trends from 2024 to 2034, DelveInsight Reports | Eloxx Pharmac, Biogen, River 3 Renal Corp, Travere Therapeutics, Chinook Therapeutics - Barchart
Alport Syndrome Treatment Market 2034: Clinical Trials, EMA, PDMA, FDA Approvals, Medication, Therapies, and Companies by DelveInsight - The Globe and Mail
Travere Therapeutics (NASDAQ:TVTX) Stock Price Down 4.2%Here's Why - MarketBeat
Travere Therapeutics Provides Corporate Update and 2025 Outlook - The Manila Times
Travere's FILSPARI Drives $50M Q4 Sales, European Expansion Gains Momentum with Multi-Country Launch - StockTitan
Travere Therapeutics (NASDAQ:TVTX) Coverage Initiated at Cantor Fitzgerald - Defense World
Wall Street Analysts Believe Travere (TVTX) Could Rally 42.56%: Here's is How to Trade - MSN
Travere Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Insider Selling: Travere Therapeutics, Inc. (NASDAQ:TVTX) Insider Sells 2,066 Shares of Stock - MarketBeat
Travere therapeutics chief medical officer sells shares totaling $47,714 By Investing.com - Investing.com Canada
Travere therapeutics chief medical officer sells shares totaling $47,714 - Investing.com
Travere Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Travere Therapeutics (NASDAQ:TVTX) Trading Up 7.2%Here's Why - MarketBeat
High Growth Tech Stocks in the United States to Watch - Simply Wall St
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Given Average Rating of “Moderate Buy” by Analysts - Defense World
Geode Capital Management LLC Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Acquired by Geode Capital Management LLC - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) CAO Sells $258,300.00 in Stock - MarketBeat
Travere therapeutics CAO Calvin Sandra sells $258,277 in stock By Investing.com - Investing.com Canada
Investing in Travere Therapeutics (NASDAQ:TVTX) a year ago would have delivered you a 82% gain - Yahoo Finance
Barclays PLC Sells 17,544 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
State Street Corp Has $38.29 Million Stake in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
CSL Vifor and Travere Therapeutics Announce Swissmedic approval of FILSPARI® (sparsentan) for the treatment of IgA Nephropathy - The Eastern Progress Online
XTX Topco Ltd Cuts Stock Position in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics: Cautiously Bullish Based On Improving Revenue (NASDAQ:TVTX) - Seeking Alpha
Travere Therapeutics' SWOT analysis: stock poised for growth amid rare disease focus - Investing.com Canada
(TVTX) Investment Analysis - Stock Traders Daily
Y Intercept Hong Kong Ltd Lowers Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Fmr LLC Acquires 31,772 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
The Manufacturers Life Insurance Company Purchases 17,931 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Travere Therapeutics' SWOT analysis: rare disease stock poised for growth By Investing.com - Investing.com Canada
TVTX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Travere Therapeutics, Inc. and Encourages Investors to Contact the Firm - The Eastern Progress Online
Charles Schwab Investment Management Inc. Sells 1,184 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Two Sigma Advisers LP Increases Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - MarketBeat
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stock Holdings Lessened by Point72 Asia Singapore Pte. Ltd. - MarketBeat
0.86%
7.33%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):